Losartan Potassium Tablet, Film Coated
Product Images NDC 71335-2083

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 71335-2083). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713352083)

Losartan Potassium Tablets USP 100 mg label with drug quantity of 30 tablets. The label includes storage instructions and safety warnings, including to keep out of reach of children and protect from light. It is repackaged by Bryant Ranch Prepack, Inc., and manufactured by Zhejiang Huahai Pharmaceutical Co., Ltd. The label displays the NDC 71335-2083-1 and features a barcode and a BRP Pharmaceuticals logo.*

FDA Label Image

Chemical Structure (Spl Image1 Structure1)

Chemical structure diagram of Losartan Potassium showing its molecular arrangement including a potassium ion (K+). The structure highlights the substituted biphenyl and imidazole rings characteristic of this active ingredient.*

FDA Label Image

Figure 1 (Spl Image2 Figure1)

A line graph comparing the percentage of patients with the primary endpoint over study months between Atenolol (dotted line) and Losartan Potassium (solid line). The x-axis represents study months from 0 to 66, and the y-axis shows the percentage of patients from 0 to 16. The graph indicates an adjusted risk reduction of 13% for Losartan Potassium with a p-value of 0.021.*

FDA Label Image

Figure 2 (Spl Image3 Figure2)

A line graph comparing the percentage of patients with fatal or non-fatal strokes over 66 study months between Losartan Potassium and Atenolol. The x-axis represents the study months, and the y-axis shows the percentage of patients affected. Losartan Potassium demonstrates a lower cumulative percentage compared to Atenolol, indicating an adjusted risk reduction of 25% (p=0.001).*

FDA Label Image

Figure 3 (Spl Image4 Figure3)

A clinical study figure displaying primary endpoint events for Losartan Potassium versus Atenolol within demographic subgroups. The chart shows event rates (%) and hazard ratios with 95% confidence intervals for the primary composite and stroke (fatal/non-fatal) outcomes across categories like age, gender, race, ISH, diabetes, and history of cardiovascular disease. Data points include the number of patients and proportional symbols representing sample sizes.*

FDA Label Image

Figure 4 (Spl Image5 Figure4)

A Kaplan-Meier curve showing the percentage of patients with an event over 48 months comparing Losartan Potassium (solid line) to placebo (dotted line). The graph indicates a 16.1% risk reduction with Losartan Potassium and includes a p-value of 0.022, demonstrating statistical significance.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.